References

nogr

Экспериментальная и клиническая гастроэнтерология

Experimental and Clinical Gastroenterology

1682-8658

«Global Media Technologies»

10.31146/1682-8658-ecg-222-2-120-130

nogr-2588

Research Article

ОБЗОР

REVIEW

Саркопения и неалкогольная жировая болезнь печени

Sarcopenia and non-alcoholic fatty liver disease

Мязин

Р. Г.

Myazin

R. G.

naclo@mail.ru

Федеральное государственное бюджетное образовательное учреждение высшего образования «Волгоградский государственный медицинский университет» Министерства Здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education «Volgograd State Medical University» of the Ministry of Health of the Russian FederationRussian Federation

2024

26032024

02120130

2024

Мязин Р.Г.

Myazin R.G.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.nogr.org/jour/article/view/2588

В литературном обзоре рассмотрена роль питания в развитии скелетной мускулатуры. Изложен патогенез развития саркопении и современные аспекты ее диагностики. Представлены возможные варианты влияния лекарственных препаратов на состояние скелетной мускулатуры и ее функциональную активность. Рассмотрена связь между саркопенией и неалкогольной жировой болезнью печени с предполагаемыми подходами к терапии данных коморбидных заболеваний.

The literature review examines the role of nutrition in the development of skeletal muscles. The pathogenesis of the development of sarcopenia and modern aspects of its diagnosis are outlined. Possible options for the influence of drugs on the state of skeletal muscles and its functional activity are presented. The relationship between sarcopenia and non-alcoholic fatty liver disease with proposed approaches to the treatment of these comorbid diseases is considered.

саркопенияпатогенездиагностикалечениенеалкогольная жировая болезнь печени

sarcopenianon-alcoholic fatty liver diseasediagnostictreatment

References1

Cruz-Jeentoft A.J., Baeyens J. P., Bauer J. M., Boirie Y., Cederholm T., Landi F., Martin F. C., Michel J.-P., Rolland Y., Schneider S. M., Topinkova E., Vandewoude M., Zamboni M. Sarcopenia: European consensus on definition and diagnosis. Report of the European Working Group on Sarcopenia in Older People. Age and Ageing. 2010; 39: 412-423 doi: 10.1093/ageing/afq034.

Cruz-Jentoft A.J., Bahat G., Bauer J. M. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019; 48(1):16-31. doi: 10.1093/ageing/afy169.

United Nations. Department of Economic and Social Affairs 2023. World Social Report 2023: leaving no one behind in an ageing world.

Zavyalova A.N., Novikova V. P., Ignatova P. D. Axis “microbiota - muscle”. Experimental and Clinical Gastroenterology. 2022;(11):60-69. (In Russ.) doi: 10.31146/1682-8658-ecg-207-11-60-69.@@ Завьялова А. Н., Новикова В. П., Игнатова П. Д. Ось «микробиота - мышцы». Экспериментальная и клиническая гастроэнтерология. 2022;207(11): 60-69. doi: 10.31146/1682-8658-ecg-207-11-60-69.

Simahodskij A. S., Leonova I. A., Pen’kov D.G., et al. Pitanie zdorovogo i bol’nogo rebenka. [Nutrition for a healthy and sick child.] Sankt- Peterburg, 2020. Vol. 1.@@ Симаходский А. С., Леонова И. А., Пеньков Д. Г., Зорина С. А., Каган А. В., Кручина Т. К., Кручина М. К., Горелик К. Д., Башнина Е. Б., Романенко О. П., Гурова М. М., Новикова В. П., Богданова Н. М., Завьялова А. Н., Алешина Е. И. Питание здорового и больного ребенка. Санкт-Петербург, 2020. Том 1.

Manickam R., Duszka K., Wahli W. PPARs and Microbiota in Skeletal Muscle Health and Wasting.Int J Mol Sci. 2020;21(21):8056. doi: 10.3390/ijms21218056.

Parenteral and enteral nutrition [Electronic resource]: national guidelines / Ed. M. Sh. Khubutia, T. S. Popova, A. I. Saltanova. Moscow. GEOTARMedia, 2015. Accessed 27.01.2024. (in Russ.)@@ Парентеральное и энтеральное питание [Электронный ресурс]: национальное руководство / Под ред. М. Ш. Хубутия, Т. С. Поповой, А. И. Салтанова. - М.: ГЭОТАРМедиа, 2015. Дата обращения 27.01.2024.

Biochemistry: a textbook for universities. Edd. prof. Danilova L. A. Saint Petersburg: SpecLit; 2020. (In Russ.)@@ Биохимия: учебник для вузов. Под ред. проф. Даниловой Л. А. СПб.: СпецЛит, 2020.

Mokrysheva N.G., Krupinova J. A., Volodicheva V. L., Mirnaya S. S., Melnichenko G. A. A view at sarcopenia by endocrinologist. Obesity and metabolism. 2018;15(3):21-27. (In Russ.) doi: 10.14341/omet9792.@@ Мокрышева Н. Г., Крупинова Ю. А., Володичева В. Л., Мирная С. С., Мельниченко Г. А. Саркопения глазами эндокринолога. Ожирение и метаболизм. 2018;15(3):21-27. doi: 10.14341/omet9792.

Perna S., Spadaccini D., Rondanelli M. Sarcopenic Obesity: Time to target the phenotypes. J Cachexia Sarcopenia Muscle. 2019;10(3):710-711. doi: 10.1002/jcsm.12425.

Drapkina O. M., Budnevsky A. V., Ovsyannikov E. S., Kontsevaya A. V., Drobysheva E. S. Sarcopenic obesity: patterns and paradoxes. Profilakticheskaya Meditsina. 2021;24(1):73-78. (In Russ.) doi: 10.17116/profmed20212401173.@@ Драпкина О. М., Будневский А. В., Овсянников Е. С., Концевая А. В., Дробышева Е. С. Саркопеническое ожирение: закономерности и парадоксы. Профилактическая медицина. 2021;24(1):73-78. doi: 10.17116/profmed20212401173.

Dao T., Green A. E., Kim Y. A., Bae S. J., Ha K. T., Gariani K., Lee M. R., Menzies K. J., Ryu D. Sarcopenia and Muscle Aging: A Brief Overview. Endocrinol Metab (Seoul). 2020;35(4):716-732. doi: 10.3803/EnM.2020.405.

Picca A., Calvani R., Cesari M., Landi F., Bernabei R., Coelho- Júnior H. J., Marzetti E. Biomarkers of Physical Frailty and Sarcopenia: Coming up to the Place? Int J Mol Sci. 2020;21(16):5635. doi: 10.3390/ijms21165635.

Bocharova K.A., Gerasimenko A. V., Zhaboeva S. L. To the question of sarkopenia association with the main geriatric syndromes. Modern problems of science and education. 2014;(6):1036-1043. (In Russ.)@@ Бочарова К. А., Герасименко А. В., Жабоева С. Л. К вопросу об ассоциации саркопении с основными гериатрическими синдромами. Современные проблемы науки и образования. 2014; 6: 1036-1043.

Noskov S.N., Zavodchikov A. A., Lavrukhina A. A., Gulneva M.Yu., Tsurko V. V. Clinical significance of sarcopenia and miopenia. RMJ. 2013; 21:1041. (In Russ.)@@ Носков С. Н., Заводчиков А. А., Лаврухина А. А., Гульнева М. Ю., Цурко В. В. Клиническое значение саркопении и миопении. РМЖ. 2013; 21:1041.

Morley J. E. Sarcopenia: diagnosis and treatment. J Nutr Hlth Aging. 2008;12(7):452-456. doi: 10.1007/bf02982705.

Paddon-Jones D., Short K. R., Campbell W. W., Volpi E., Wolfe R. R. Role of dietary protein in the sarcopenia of aging. Am J Clin Nutr. 2008 May;87(5):1562S-1566S. doi: 10.1093/ajcn/87.5.1562s.

Ticinesi A., Nouvenne A., Cerundolo N., Catania P., Prati B., Tana C., Meschi T. Gut Microbiota, Muscle Mass and Function in Aging: A Focus on Physical Frailty and Sarcopenia. Nutrients. 2019;11(7):1633. doi: 10.3390/nu11071633.

De Sire R., Rizzatti G., Ingravalle F. et al. Skeletal muscle-gut axis: emerging mechanisms of sarcopenia for intestinal and extra intestinal diseases. Minerva Gastroenterol Dietol. 2018 Dec;64(4):351-362. doi: 10.23736/s1121-421x.18.02511-4.

Zavyalova A.N., Khavkin A. I., Novikova V. P. Causes and prevention options for sarcopenia in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2022;67(2):34-42. (In Russ.) doi: 10.21508/1027-4065-2022-67-2-34-42.@@ Завьялова А. Н., Хавкин А. И., Новикова В. П. Причины и варианты профилактики саркопении у детей. Российский вестник перинатологии и педиатрии. 2022; 67 (2): 34-42. doi: 10.21508/1027-4065-2022-67-2-34-42.

Bukvalnaya N. V., Yakubova L. V., Pitsko D. V., Goncharuk I. A. Sarcopenia: focus on updated recommendations. Medical business. 2019;70(6):30-35. (In Russ.)@@ Буквальная Н. В., Якубова Л. В., Пицко Д. В., Гончарук И. А. Саркопения: акцент на обновленные рекомендации. Лечебное дело. 2019. Т. 70. № 6. С. 30-35.

Franzke B., Neubauer O., Cameron-Smith D., Wagner K-H. Dietary protein, muscle and physical function in the very old. Nutrients. 2018 Jul 20;10(7):935. doi: 10.3390/nu10070935.

Bhatia V., Singh R., Acharya S. K. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut. 2006 Jan;55(1):98-104. doi: 10.1136/gut.2004.061754.

Shalimar Sheikh M. F., Mookerjee R. P., Agarwal B., Acharya S. K., Jalan R. Prognostic Role of Ammonia in Patients with Cirrhosis. Hepatology. 2019 Sep;70(3):982-994. doi: 10.1002/hep.30534.

Goodpaster B.H., Park S. W., Harris T. B. et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol a Biol Sci Med Sci. 2006 Oct;61(10):1059-64. doi: 10.1093/gerona/61.10.1059.

Yang Y.J, Kim D. J. An Overview of the Molecular Mechanisms Contributing to Musculoskeletal Disorders in Chronic Liver Disease: Osteoporosis, Sarcopenia, and Osteoporotic Sarcopenia.International Journal of Molecular Sciences. 2021; 22(5):2604. doi: 10.3390/ijms22052604.

Giudice J., Taylor J. M. Muscle as a paracrine and endocrine organ. Curr Opin Pharmacol. 2017 Jun;34:49-55. doi: 10.1016/j.coph.2017.05.005.

Paltsyn A. A. Myokines. Pathological Physiology and Experimental Therapy, Russian Journal. 2020; 64(1): 135-141. (in Russ.) doi: 10.25557/0031-2991.2020.01.135-141.@@ Пальцын А. А. Миокины. Патологическая физиология и экспериментальная терапия. 2020; 64(1): 135-141. doi: 10.25557/0031-2991.2020.01.135-141.

Severinsen M.C.K., Pedersen B. K. Muscle-Organ Crosstalk: The Emerging Roles of Myokines. Endocr Rev. 2020 Aug 1;41(4):594-609. doi: doi: 10.1210/endrev/bnaa016.

Mancinelli R., Checcaglini F., Coscia F., Gigliotti P., Fulle S., FanòIllic G. Biological Aspects of Selected Myokines in Skeletal Muscle: Focus on Aging.Int J Mol Sci. 2021 Aug 7;22(16):8520. doi: 10.3390/ijms22168520.

Suriano F., Van Hul M., Cani P. D. Gut microbiota and regulation of myokine- adipokine function. Curr Opin Pharmacol. June 2020; 52:9-17. doi: 10.1016/j.coph.2020.03.006.

Lahiri S., Kim H., Garcia-Perez I., et al. The gut microbiota influences skeletal muscle mass and function in mice. Sci Transl Med. 24 Jul 2019;11(502). doi: 10.1126/scitranslmed.aan5662.

Grosicki G.J., Fielding R. A., Lustgarten M. S. Gut Microbiota Contribute to Age- Related Changes in Skeletal Muscle Size, Composition, and Function: Biological Basis for a Gut- Muscle Axis. Calcif Tissue Int. 2018;102(4):433-442. doi: 10.1007/s00223-017-0345-5.

Spychala M.S., Venna V. R., Jandzinski M., et al. Agerelated changes in the gut microbiota influence systemic inflammation and stroke outcome. Ann Neurol. 07 May 2018;84(1):23-36. doi: 10.1002/ana.25250.

Gizard F., Fernandez A., De Vadder F.Interactions between gut microbiota and skeletal muscle. Nutr Metab Insights. 2020;13. doi: 10.1177/1178638820980490.

Erokhina A. S., Golovanova E. D. The relationship between comorbidity and sarcopenia: impact on mortality and survival. Doctor. 2021, No.6, pp. 60-64. (In Russ.) doi: 10.29296/25877305-2021-06-11.@@ Ерохина А. С., Голованова Е. Д. Взаимосвязь коморбидности и саркопении: влияние на смертность и выживаемость. Врач. 2021. № 6. С. 60-64. doi: 10.29296/25877305-2021-06-11.

Lera L., Angel B., Marquez C., Saguez R., Albala C. Besides Sarcopenia, Pre-Sarcopenia Also Predicts All-Cause Mortality in Older Chileans. Clin Interv Aging. 2021;16: 611-619. doi: 10.2147/CIA.S289769.

Malmstrom T. K. Morley J. E. SARC-F: A Simple Questionnaire to Rapidly Diagnose Sarcopenia. J Am Med Dir Assoc. 2013 Aug;14(8):531-2. doi: 10.1016/j.jamda.2013.05.018.

Issa D., Alkhouri N., Tsien C. et al. Presence of sarcopenia (muscle wasting) in patients with nonalcoholic steatohepatitis. Hepatology (Baltimore, Md.). 2014 Jul;60(1):428-429. doi: 10.1002/hep.26908.

Bredella M. A., Ghomi R. H., Thomas B. J., Torriani M., Brick D. J., Gerweck A. V., Misra M., Klibanski A., Milleret K. K.Comparison of DXA and CT in the assessment of body composition in premenopausal women with obesity and anorexia nervosa. Obesity (Silver Spring). 2010; 18:2227-2233. doi: 10.1038/oby.2010.5.

Grinevich V. B., Sas E. I. The role of sarcopenia in the development of non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2020;183(11):70-73. (In Russ.) doi: 10.31146/1682-8658-ecg-183-11-70-73.@@ Гриневич В. Б., Сас Е. И. Роль саркопении в развитии неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2020;183(11): 70-73. doi: 10.31146/1682-8658-ecg-183-11-70-73.

Landi F., Cruz-Jentoft A. J., Liperoti R., Russo A., Giovannini S., Tosato M., Capoluongo E., Bernabei R., Onder G. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from ilSIRENTE study. Age Ageing. 2013 Mar;42(2):203-9. doi: 10.1093/ageing/afs194.

Grigorieva I. I., Raskina T. A., Letaeva M. V., Malyshenko O. S., Averkieva Yu.V., Masenko V. L., Kokov A. N. Sarcopenia: pathogenesis and diagnosis. Fundamental and Clinical Medicine. 2019;4(4):105-116. (In Russ.) doi: 10.23946/2500-0764-2019-4-4-105-116.@@ Григорьева И. И., Раскина Т. А., Летаева М. В., Малышенко О. С., Аверкиева Ю. В., Масенко В. Л., Коков А. Н. Саркопения: особенности патогенеза и диагностики. Фундаментальная и клиническая медицина. 2019;4(4):105-116. doi: 10.23946/2500-0764-2019-4-4-105-116.

Erokhina A. S., Golovanova E. D., Miloserdov M. A. Ultrasound assessment of muscle mass in the diagnosis of sarcopenia in cardiovascular patients. Cardiovascular Therapy and Prevention. 2021;20(3):2699. (In Russ.) doi: 10.15829/1728-8800-2021-2699.@@ Ерохина А. С., Голованова Е. Д., Милосердов М. А. Роль ультразвуковой оценки мышечной массы в диагностике саркопении у пациентов с сердечно-сосудистыми заболеваниями. Кардиоваскулярная терапия и профилактика. 2021;20(3):2699. doi: 10.15829/1728-8800-2021-2699.

Ido A., Nakayama Y., Ishii K., Iemitsu M., Sato K., Fujimoto M., Kurihara T., Hamaoka T., Satoh-Asahara N., Sanadaet K. Ultrasound-derived abdominal muscle thickness better detects metabolic syndrome risk in obese patients than skeletal muscle index measured by dual energy X-ray absorptiometry. PLoS One. 2015;10(12):0143858. doi: 10.1371/journal.pone.0143858.

Sanada K., Kuchiki T., Miyachi M., McGrath K., Higuchi M., Ebashi H. Effects of age on ventilator threshold and peak oxygen uptake normalized for regional skeletal muscle mass in Japanese men and women aged 20-80 years. Eur J Appl Physiol. 2007;99(5):475-83. doi: 10.1007/s00421-006-0375-6.

Nijholt W., Scafoglieri A., Jager-Wittenaar H., Van der Schans C. P. The reliability and validity of ultrasound to quantify muscles in older adults: a systematic review. J Cachexia Sarkopenia Muscle. 2017;8(5):702-12. doi: doi: 10.1002/jc.

Stenholm S., Harris T. B., Rantanen T., Visser M., Kritchevsky S. B., Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):693-700. doi: 10.1097/mco.0b013e328312c37d.

Janssen J., Heimsfield S. B., Baumgartner R. N., Ross R. Estimation of skeletal muscle mass by bioelectrical impedance analysis. J Appl Physiol. 2000, 89(2):465-471. doi: 10.1152/jappl.2000.89.2.465.

Van Kan G. A., Rolland Y., Andrieu S. et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J Nutr Health Aging. 2009 13(10):881-889. doi: 10.1007/s12603-009-0246-z.

Sas E. I., Barnakova V. A. Skeletal muscle hormone activity and non-alcoholic fatty liver disease. Medical alphabet. 2020;(17):31-34. (In Russ.) doi: 10.33667/2078-5631-2020-17-31-34.@@ Сас Е. И., Барнакова В. А. Гормональная активность скелетной мускулатуры и неалкогольная жировая болезнь печени. Медицинский алфавит. 2020; (17): 31-34. doi: 10.33667/2078-5631-2020-17-31-34.

Lazebnik L. B., Golovanova E. V., Turkina S. V. et al. Non-alcoholic fatty liver disease in adults: clinic, diagnostics, treatment. Guidelines for therapists, third version. Experimental and Clinical Gastroenterology. 2021;1(1):4-52. (In Russ.) doi: 10.31146/1682-8658-ecg-185-1-4-52.@@ Лазебник Л. Б., Голованова Е. В., Туркина С. В. и Соавт. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия. Экспериментальная и клиническая гастроэнтерология. 2021;1(1):4-52. doi: 10.31146/1682-8658-ecg-185-1-4-52.

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64: 1388-1402.

Gómez A., Romero-Gómez M., Ampuero J. Glutaminolysisammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease. Progression and Development of Novel Therapies. J Clin Transl Hepatol. 2022;10(2):356-362. doi: 10.14218/JCTH.2021.00247.

Mishina E.E., Mayorov A. Y., Bogomolov P. O., Matsievich M. V., Kokina K. Y., Bogolyubova A. V. Nonalcoholic fatty liver disease: cause or consequence of insulin resistance? Diabetes mellitus. 2017;20(5):335-343. (In Russ.) doi: 10.14341/DM9372.@@ Мишина Е. Е., Майоров А. Ю., Богомолов П. О., Мациевич М. В., Кокина К. Ю., Боголюбова А. В. Неалкогольная жировая болезнь печени: причина или следствие инсулинорезистентности? Сахарный диабет. 2017. Т. 20, 5: 335-342. doi: 10.14341/DM9372.

Angulo P., Kleiner D. E., Dam-Larsen S. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015 April 29;149(2):389-397. doi: 10.1053/j.gastro.2015.04.043.

Chalasani N., Younossi Z., Lavine J. E., Charlton M., Cusi K., Rinella M., Harrison S. A., Brunt E. M., Arun S. J. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-57. doi: 10.1002/hep.29367.

Chitturi S., Wong V. W., Chan W. K. et al. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups. J Gastroenterol Hepatol. 2018 Jan;33(1):86-98. doi: 10.1111/jgh.13856.

Chelakkot C., Ghim J., Ryu S. H. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018 Aug 16; 50(8):1-9. doi: 10.1038/s12276-018-0126-x.

Lim S., Kim J. H., Yoon J. W. et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care. 2010; 33: 1652-1654. doi: 10.2337%2Fdc10-0107.

Kim T.N., Park M. S., Yang S. J. et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care. 2010 Jul;33(7):1497-1499. doi: 10.2337/dc09-2310.

Kim S. W. Jung H. W. Which one is associated with nonalcoholic fatty liver disease? Small muscle mass or large fat mass. Hepatology. 2015; 61: 1764. doi: 10.1002/hep.27370.

Zi-Xuan Wang, Meng-Yu Wang, Rui-Xu Yang, Ze-Hua Zhao, Feng-Zhi Xin, Yu Li, Tian-Yi Ren, Jian-Gao Fan. Ammonia Scavenger Restores Liver and Muscle Injury in a Mouse Model of Non-alcoholic Steatohepatitis with Sarcopenic Obesity. Front Nutr. 2022 Mar 17;9: 808497. doi: 10.3389/fnut.2022.808497.

Zhang C., McFarlane C., Lokireddy S., Bonala X. G., Masuda S., Gluckman P. D., Sharma M., Kambadur R. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway. Diabetologia. 2011; 54: 1491-1501. doi: 10.1007/s00125-011-2079-7.

Dasarathy S., Muc S., Runkana A. Mullen K. D. Alteration in body composition in the portacaval anastamosis rat is mediated by increased expression of myostatin. Am J Physiol Gastrointest Liver Physiol. 2011 Oct;301(4): G731-8. doi: 10.1152/ajpgi.00161.2011.

Seldin M.M., Peterson J. M., Byerly M. S., Wei Z., Wong G. W. Myonectin (CTRP15), a novel myokine that links skeletal muscle to systemic lipid homeostasis. J Biol Chem. 2012; 287: 11968-11980. doi: 10.1074/jbc.m111.336834

Bonala S., McFarlane C., Ang J. et al. Retraction: Pid1 Induces Insulin Resistance in Both Human and Mouse Skeletal Muscle during Obesity. Molecular Endocrinology. 2013 Sep;27(9):1518-35. doi: 10.1210/me.2013-1048.

Zykina E. J., Simonova Zh. G. Hyperammonemia in patients with stable angina pectoris and nonalcoholic fatty liver disease at the steatosis stage. Experimental and Clinical Gastroenterology. 2023;(8):57-65. (In Russ.) doi: 10.31146/1682-8658-ecg-216-8-57-65.@@ Зыкина Е. Ю., Симонова Ж. Г. Гипераммониемия у пациентов со стабильной стенокардией и неалкогольной жировой болезнью печени на стадии стеатоза. Экспериментальная и клиническая гастроэнтерология. 2023;(8):57-65. doi: 10.31146/1682-8658-ecg-216-8-57-65.

Lazebnik L. B., Golovanova E. V., Alekseenko S. A. et al.Russian Consensus “Hyperammonemia in Adults” (Version 2021). Experimental and Clinical Gastroenterology. 2021;(3):97-118. (In Russ.) doi: 10.31146/1682-8658-ecg-187-3-97-118.@@ Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и соавт. Российский консенсус «Гипераммониемии у взрослых» (Версия 2021). Экспериментальная и клиническая гастроэнтерология. 2021;(3):97-118. doi: 10.31146/1682-8658-ecg-187-3-97-118.

Lee Y.H., Jung K. S., Kim S.U, Yoon H. J., Yun Y. J., Lee B-W., Kang E. S., Han K-H., Lee H. C., Cha B-S. Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015; 63: 486-493. doi: 10.1016/j.jhep.2015.02.051.

Qiu J., Tsien C., Thapalaya S., Narayanan A. et al. Hyperammonemia-mediated autophagy in skeletal muscle contributes to sarcopenia of cirrhosis. Am J Physiol Endocrinol Metab. 2012. 303(8), E983-E993. doi: 10.1152/ajpendo.00183.2012.

Dasarathy S., Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016 August 08; 65(6):1232-1244. doi: 10.1016/j.jhep.2016.07.040.

Roubenoff R., Hughes V. A. Sarcopenia: current concepts. J Gerontol a Biol Sci Med Sci. 2000 Dec; 55(12): M716-24. doi: 10.1093/gerona/55.12.m716.

Janssen I., Heymsfield S. B., Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc. 2002; 50(5): 889-96. doi: 10.1046/j.1532-5415.2002.50216.x.

Janssen I., Shepard D. S., Katzmarzyk P. T., Roubenoff R. The healthcare costs of sarcopenia in the United States. J Am Geriatr Soc. 2004 Jan;52(1): 80-5. doi: 10.1111/j.1532-5415.2004.52014.x.

Gale C.R., Martyn C. N., Cooper C., Sayer A. A. Grip strength, body composition, and mortality.International Journal of Epidemiology. 2007;36(1): 228-235. doi: 10.1093/ije/dyl224.

Pichon C., Nachit M., Gillard J., Velde G. V., Lanthier N., Leclercq I. A. Impact of L-ornithine L-aspartate on non-alcoholic steatohepatitis-associated hyperammonemia and muscle alterations. Frontiers in Nutrition. 2022 Nov 16;9: 1051157. doi: 10.3389/fnut.2022.1051157.

Dasarathy S., Muc S., Hisamuddin K., Edmison J. M., Dodig M., McCullough A. J., Kalhan S. C. Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol. 2007; 292: G1105-G1113. doi: 10.1152/ajpgi.00529.2006.

Sanzgiri U.Y., Srivatsan V., Muralidhara S., Dallas C. E., Bruckner J. V. Uptake, distribution, and elimination of carbon tetrachloride in rat tissues following inhalation and ingestion exposures. Toxicol Appl Pharmacol. 1999; 143: 120-129. doi: 10.1006/taap.1996.8079.

Bucci L., Hickson J. F., Pivarnik J. M., Wolinsky I., McMahon J. C., Turner S. D. Ornithine ingestion and growth hormone release in bodybuilders. Nutrition Research. 1990; 10 (3): 239-245. doi: 10.1016/S0271-5317(05)80265-9.

Butterworth R.F., Canbay A. Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. Digestive Diseases. 2019;37(1):63-68. doi: 10.1159/000491429.

Butterworth R.F. L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle. Can J Gastroenterol Hepatol. 2019:8182195. doi: 10.1155/2019/8182195.

Kumar A., Davuluri G., Silva R. N.E., Engelen M. P.K.J., Ten Have G. A.M., Prayson R., Deutz N. E.P., Dasarathy S. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology. 2017 Jun;65(6):2045-2058. doi: 10.1002/hep.29107.

Butterworth R.F., Kircheis G., Hilger N., McPhail M. J.W. Efficacy of l-ornithine l-aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta-analysis of randomized controlled trials. J Clin Exp Hepatol. 2018; 8(3):301-13. doi: 10.1016/j.jceh.2018.05.004.

Canbay A., Sowa J-P. L-ornithine L-aspartate (LOLA) as a novel approach for therapy of Non-alcoholic Fatty Liver Disease. Drugs. 2019; 79 (Suppl 1): S39-S44. doi: 10.1007/s40265-018-1020-5.

Rojas A., García-Lozano M. R., Gil-Gómez A., Romero-Gómez M., Ampuero J. Glutaminolysis-ammonia-urea Cycle Axis, Non-alcoholic Fatty Liver Disease Progression and Development of Novel Therapies. Journal of Clinical and Translational Hepatology. 2022; 10(2):356-362. doi: 10.14218/JCTH.2021.00247.

Gairing S.J., Müller L., Kloeckner R., Galle P. R., Labenz C. Review article: post-TIPSS hepatic encephalopathy-current knowledge and future perspectives. Alimentary Pharmacology & Therapeutics. 2022, 18 February. 1265-1276. doi: 10.1111/apt.16825.

Jain A., Sharma B. C., Mahajan B., Srivastava S., Kumar A., Sachdeva S. et al.Intravenous l-ornithine l-aspartate in acute treatment of severe hepatic encephalopathy. Journal of Clinical and Experimental Hepatology. 2022, 12(3):1003-1006. doi: 10.1016/j.jceh.2022.04.003.

Butterworth R.F. L-Ornithine L-Aspartate: Multimodal Therapeutic Agent for Hyperammonemia and Hepatic Encephalopathy in Cirrhosis. Journal of Pharmacology and Pharmaceutical Research. 2019 June;2(3). doi: doi: 10.31038/jppr.2019234.

Kamimura H., Sato T., Natsui K. et al. Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge.International Journal of Molecular Sciences. 2021; 22(3):1425. doi: 10.3390/ijms22031425.

Bajaj J.S., Riggio O. Drug therapy: Rifaximin. Hepatology. 2010 Oct; 52(4): 1484-8. doi: doi: 10.1002/hep.23866.

Kimer N., Krag A., Gluud L. L. Safety, efficacy, and patient acceptability of Rifaximin for hepatic encephalopathy. Patient Prefer. Adherence. 2014 Mar 18; 8:331-8. doi: 10.2147/PPA.S41565.

Sharma B.C., Sharma P., Lunia M. K., Srivastava S., Goyal R., Sarin S. K. A randomized, double-blind, controlled trial comparing Rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am. J. Gastroenterol. 2013 Sep; 108(9): 1458-63. doi: 10.1038/ajg.2013.219.

The authors declare that there are no conflicts of interest present.